within Pharmacolibrary.Drugs.ATC.R;

model R03CC05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 0.25,
    adminDuration  = 600,
    adminMass      = 0.02,
    adminCount     = 1,
    Vd             = 0.0025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00038333333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Hexoprenaline is a selective beta-2 adrenergic agonist primarily used as a bronchodilator in the treatment of asthma and chronic obstructive pulmonary disease (COPD). It has also been used in obstetrics for tocolysis (suppression of preterm labor). Hexoprenaline is still in use in some countries but is not available or approved in all regions.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters based on class properties of beta-2 agonists and available summary information. No published human compartmental pharmacokinetic model specific to hexoprenaline identified.</p><h4>References</h4><ol><li>J Lipshitz, M K Yau, M C Meyer, R A Ahokas, A L Maduska, W D Whybrew, G D Anderson, J C Morrison, J Schneider,Hexoprenaline pharmacokinetics in pregnant and nonpregnant sheep.,Research communications in chemical pathology and pharmacology,1981<a href='https://pubmed.ncbi.nlm.nih.gov/7313303/'>https://pubmed.ncbi.nlm.nih.gov/7313303/</a></li><li>J McCombs,Update on tocolytic therapy.,The Annals of pharmacotherapy,1995<a href='https://pubmed.ncbi.nlm.nih.gov/7655136/'>https://pubmed.ncbi.nlm.nih.gov/7655136/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R03CC05;
